Research / BURL / Fundamental state Inspectable configuration
State dimensions Filing 0001193125-26-371311 General Corporate
Debt relative to revenue 50th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.debt_to_revenue
63.16% · OPTIONAL · VALID
Capex intensity 75th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.capex_revenue_ratio
8.13% · OPTIONAL · VALID
Operating cash generation 85th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
9.11% · OPTIONAL · VALID
Share-count growth 70th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.shares_outstanding
-0.35% · CORE · VALID
Revenue growth 65th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
10.99% · CORE · VALID
Inventory pressure 50th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
51.42% · OPTIONAL · VALID
Gross margin 100th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_margin
46.16% · CORE · VALID
SBC intensity 90th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
1.07% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 45 states Self-history eligible
Oct 30, 2021 8/8 normalized Level 3 Jan 29, 2022 7/7 normalized Level 3 Apr 30, 2022 8/8 normalized Level 3 Jul 30, 2022 8/8 normalized Level 3 Oct 29, 2022 8/8 normalized Level 3 Jan 28, 2023 7/7 normalized Level 3 Apr 29, 2023 8/8 normalized Level 3 Jul 29, 2023 8/8 normalized Level 3 Oct 28, 2023 8/8 normalized Level 3 Feb 3, 2024 7/7 normalized Level 3 May 4, 2024 8/8 normalized Level 3 Aug 3, 2024 8/8 normalized Level 3 Nov 2, 2024 8/8 normalized Level 3 Feb 1, 2025 7/7 normalized Level 3 May 3, 2025 8/8 normalized Level 3 Aug 2, 2025 8/8 normalized Level 3 Nov 1, 2025 8/8 normalized Level 3 Jan 31, 2026 7/7 normalized Level 3 May 2, 2026 8/8 normalized Level 3 Aug 1, 2026 8/8 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 66.52%
Current 63.16%
Delta -3.36% Capex Intensity Decreased
Previous 10.12%
Current 8.13%
Delta -1.99% Cash Generation Increased
Previous 2.15%
Current 9.11%
Delta 6.96% Dilution Decreased
Previous -0.23%
Current -0.35%
Delta -0.12% Growth Decreased
Previous 14.09%
Current 10.99%
Delta -3.10% Inventory Pressure Increased
Previous 50.63%
Current 51.42%
Delta 0.78% Margin Increased
Previous 44.09%
Current 46.16%
Delta 2.07% Sbc Intensity Decreased
Previous 1.27%
Current 1.07%
Delta -0.20% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Aug 4, 2018
Similarity 87%
Compared 6 dimensions
Coverage 75% Growth 10.0 · Margin 12.5 · Sbc Intensity 10.0 · Capex Intensity 15.0 · Inventory Pressure 6.3 · Balance Sheet Leverage 18.8 Oct 28, 2023
Similarity 87%
Compared 8 dimensions
Coverage 100% Growth 10.0 · Margin 15.0 · Dilution 5.0 · Sbc Intensity 10.0 · Capex Intensity 5.0 · Cash Generation 10.0 · Inventory Pressure 20.0 · Balance Sheet Leverage 20.0 Oct 29, 2016
Similarity 83%
Compared 5 dimensions
Coverage 63% Margin 0.0 · Sbc Intensity 0.0 · Capex Intensity 8.3 · Inventory Pressure 20.0 · Balance Sheet Leverage 30.0 Nov 2, 2019
Similarity 83%
Compared 7 dimensions
Coverage 88% Growth 23.8 · Margin 0.0 · Dilution 20.0 · Sbc Intensity 15.0 · Capex Intensity 10.0 · Inventory Pressure 5.0 · Balance Sheet Leverage 25.0 Aug 2, 2025
Similarity 82%
Compared 8 dimensions
Coverage 100% Growth 15.0 · Margin 20.0 · Dilution 5.0 · Sbc Intensity 5.0 · Capex Intensity 0.0 · Cash Generation 35.0 · Inventory Pressure 5.0 · Balance Sheet Leverage 25.0 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.